Abstract
Melanoma is considered an epidemic cancer as its incidence has increased 697% between 1950 and 2000, and continues to increase, faster than any other cancer subtype. Each year, over 53,000 Americans will be diagnosed with melanoma and over 7,000 will die from their disease. While representing <7% of all skin malignancies, melanoma accounts for ∼75% of all deaths from skin tumors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Demierre MF, Sabel MS, Margolin KA, et al. State of the science 60th anniversary review: 60 years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer. 2008;113(7 Suppl):1728–43.
Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666–74.
Larson AR, Konat E, Alani RM. Melanoma biomarkers: current status and vision for the future. Nat Clin Pract Oncol. 2009;6:105–17.
Rezaul K, Wilson LL, Han DK. Direct tissue proteomics in human diseases: potential applications to melanoma research. Expert Rev Proteomics. 2008;5: 405–12.
Takata M, Saida T. Genetic alterations in melanocytic tumors. J Dermatol Sci. 2006;43:1–10.
Clinical proteomic technologies for cancer. http://proteomics.cancer.gov/. Accessed 5 March 2011.
Kondo T. Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. BMB Rep. 2008;41:626–34.
Zanivan S, Gnad F, Wickström SA, et al. Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res. 2008;7: 5314–26.
Culp WD, Neal R, Massey R, et al. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res. 2006;5: 1332–43.
Hood BL, Grahovac J, Flint MS, et al. Proteomic analysis of laser microdissected melanoma cells from skin organ cultures. J Proteome Res. 2010;9: 3656–63.
Fetsch PA, Simone NL, Bryant-Greenwood PK, et al. Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol. 2002;118: 870–6.
Huang SK, Darfler MM, Nicholl MB, et al. LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis. PLoS One. 2009;4:e4430.
Rezaul K, Murphy M, Lundgren DH, et al. Combined mass spectrometry- and immunohistochemistry-based approach to determine protein expression in archival melanoma–proof of principle. Pigment Cell Melanoma Res. 2010;23:849–52.
Lazova R, Seeley E, Keenan M, et al. Mass spectrometry – a promising method to differentiate spitz nevi for spitzoid malignant melanoma [abstract]. Am J Dermatopathol. 2011;33:418.
Paulitschke V, Kunstfeld R, Mohr T, et al. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res. 2009;8: 2501–10.
Findeisen P, Peccerella T, Neumaier M, Schadendorf D. Proteomics for biomarker discovery in malignant melanoma. Expert Rev Dermatol. 2008;3: 209–20.
Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101:452–74.
Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433–44.
Carlson JA, Ross J, Murphy M. Markers of high-risk cutaneous melanoma: is there a winning combination for individualized prognosis? J Cutan Pathol. 2005;32: 700–3.
Bagnato C, Thumar J, Hwang S, et al. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid-chromatography and tandem mass spectrometry. Mol Cell Proteomics. 2007;6:1088–102.
Hwang S-I, Thumar J, Lundgren DH, et al. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin embedded archival tissues. Oncogene. 2007;26:65–76.
Fowler CB, Cunningham RE, O’Leary TJ, Mason JT. ‘Tissue surrogates’ as a model for archival formalin-fixed paraffin-embedded tissues. Lab Invest. 2007;87: 836–46.
Sprung Jr RW, Brock JW, Tanksley JP, et al. Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis. Mol Cell Proteomics. 2009;8:1988–98.
Guo T, Wang W, Rudnick PA, et al. Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J Histochem Cytochem. 2007; 55:763–72.
Nestin: human protein atlas. http://www.proteinatlas.org/tissue_profile.php?antibody_id=5889&g_no=ENSG00000132688. Accessed 5 March 2011.
Bakos RM, Maier T, Besch R, et al. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Exp Dermatol. 2010;19:e89–94.
Tanabe K, Amoh Y, Kanoh M, et al. Prognostic significance of the hair follicle stem cell marker nestin in patients with malignant melanoma. Eur J Dermatol. 2010;20:283–8.
Piras F, Perra MT, Murtas D, et al. The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep. 2010;23:17–24.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Murphy, M.J., Rezaul, K., Han, D.K. (2012). Tissue-Based Protein Biomarkers in Melanoma: Mass Spectrometry-Based Strategies. In: Murphy, M. (eds) Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Current Clinical Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-433-3_14
Download citation
DOI: https://doi.org/10.1007/978-1-60761-433-3_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-60761-432-6
Online ISBN: 978-1-60761-433-3
eBook Packages: MedicineMedicine (R0)